OMB Control Number: Not assigned, new information collection.

Type of Respondent/Affected Public: Private Sector, Businesses or other for profits, Not-for-profit institutions.

Frequency: Once.

Estimated Number of Respondents per Year: 1,400.

Estimated Time per Respondent: 0.1 hours.

Estimated Total Annual Burden Hours: 140 hours.

Abstract: The IAF works to promote sustainable development in Latin America and the Caribbean by directly supporting qualified civil society organizations through funding actions, such as grants and cooperative agreements. This collection will allow grant seekers to register for a new online IAF grant portal if they meet basic eligibility requirements. Transition to an online portal will allow electronic grant application and reporting which will increase the efficiency of IAF's grant management program.

#### **Summary Form Under Review**

*Title of Collection:* Grant Application, IAF–02.

*Type of Review:* New information collection.

*OMB Control Number:* Not assigned, new information collection.

Type of Respondent/Affected Public: Private Sector, Businesses or other for profits, Not-for-profit institutions.

Frequency: Once.

Estimated Number of Respondents per Year: 1,400.

Estimated Time per Respondent: 14 hours.

Estimated Total Annual Burden Hours: 19,600 hours.

*Abstract:* The IAF works to promote sustainable development in Latin America and the Caribbean by directly supporting qualified civil society organizations through funding actions, such as grants and cooperative agreements. This collection will gather application information directly from grant seekers including details about the applicant's organization, the development opportunity, and proposed project activities. Using this information, IAF is able to perform an initial assessment of the proposed project and determine which applicants are qualified as well as which projects are best positioned to advance grassroots development in the region. The IAF has made an effort to standardize the basic level of information required for this review in order to reduce the burden on both applicants and IAF staff reviewing the applications.

#### **Summary Form Under Review**

Title of Collection: Grant Programmatic and Financial Reporting, IAF-03.

*Type of Review:* New information collection.

*OMB Control Number:* Not assigned, new information collection.

Type of Respondent/Affected Public: Private Sector, Businesses or other for profits, Not-for-profit institutions.

Frequency: Twice a year.

Estimated Number of Respondents per year: 450.

Estimated Time per Respondent: 18 hours.

Estimated Total Annual Burden Hours: 16,200 hours.

Abstract: The IAF works to promote sustainable development in Latin America and the Caribbean by directly supporting qualified civil society organizations through funding actions, such as grants and cooperative agreements. In order to track grant progress toward desired results and ensure compliance with the terms and conditions of the agreement, the IAF seeks to establish a requirement that grantees provide programmatic and financial information every six months during the grant period, including reporting on project indicators, narrative data on grant achievements and challenges, and a record of spent funds.

This information is necessary as it allows IAF to ensure that the grantee is using project funds responsibly and making the necessary strides toward achieving the results laid out in the grant agreement.

Dated: November 3, 2023.

#### Nicole Stinson,

Associate General Counsel, Office of the General Counsel.

[FR Doc. 2023–24710 Filed 11–7–23; 8:45 am]

BILLING CODE 7025-01-P

## INTERNATIONAL TRADE COMMISSION

[Investigation No. 731–TA–921 (Fourth Review)]

## Folding Gift Boxes From China; Determination

On the basis of the record <sup>1</sup> developed in the subject five-year review, the United States International Trade Commission ("Commission") determines, pursuant to the Tariff Act of 1930 ("the Act"), that revocation of the antidumping duty order on folding gift boxes from China would be likely to lead to continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time.

#### Background

The Commission instituted this review on June 1, 2023 (88 FR 35917) and determined on September 5, 2023, that it would conduct an expedited review (88 FR 67813, October 2, 2023).

The Commission made this determination pursuant to section 751(c) of the Act (19 U.S.C. 1675(c)). It completed and filed its determination in this review on November 3, 2023. The views of the Commission are contained in USITC Publication 5471 (November 2023), entitled Folding Gift Boxes from China: Investigation No. 731–TA–921 (Fourth Review).

By order of the Commission. Issued: November 3, 2023.

#### Lisa Barton.

Secretary to the Commission.

[FR Doc. 2023–24703 Filed 11–7–23; 8:45 am]

BILLING CODE 7020-02-P

## INTERNATIONAL TRADE COMMISSION

[USITC SE-23-054]

### **Sunshine Act Meetings**

AGENCY HOLDING THE MEETING: United States International Trade Commission.

TIME AND DATE: November 17, 2023 at 11 a m

**PLACE:** Room 101, 500 E Street SW, Washington, DC 20436, Telephone: (202) 205–2000.

**STATUS:** Open to the public.

#### MATTERS TO BE CONSIDERED:

- 1. Agendas for future meetings: none.
- 2. Minutes.
- 3. Ratification List.
- 4. Commission vote on Inv. Nos 701– TA–695–698 and 731–TA–1643–1657 (Preliminary) (Aluminum Extrusions from China, Colombia, Dominican Republic, Ecuador, India, Indonesia, Italy, Malaysia, Mexico, South Korea, Taiwan, Thailand, Turkey, United Arab Emirates, and Vietnam). The Commission currently is scheduled to complete and file its determinations on November 20, 2023; views of the Commission currently are scheduled to be completed and filed on November 28, 2023.
- 5. Outstanding action jackets: none. **CONTACT PERSON FOR MORE INFORMATION:** Sharon Bellamy, Supervisory Hearings and Information Officer, 202–205–2000.

The Commission is holding the meeting under the Government in the

<sup>&</sup>lt;sup>1</sup>The record is defined in § 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).

Sunshine Act, 5 U.S.C. 552(b). In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission. Issued: November 6, 2023.

#### Sharon Bellamy,

Supervisory Hearings and Information Officer.

[FR Doc. 2023–24812 Filed 11–6–23; 11:15 am] BILLING CODE 7020–02–P

#### **DEPARTMENT OF JUSTICE**

#### **Drug Enforcement Administration**

[Docket No. DEA-1287]

#### Importer of Controlled Substances Application: Noramco

**AGENCY:** Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

**SUMMARY:** Noramco has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before December 8, 2023. Such persons may also file a written request for a hearing on the application on or before December 8, 2023.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement

Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on October 4, 2023, Noramco, 500 Swedes Landing Road, Wilmington, Delaware 19801–4417, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I
Marihuana	7360	1
Tetrahydrocannabinols	7370	1
Nabilone	7379	II
Phenylacetone	8501	П
Opium, Raw	9600	П
Opium Extracts	9610	П
Opium Fluid Extract	9620	П
Opium Tincture	9630	II
Opium Powdered	9639	II
Opium Granulated	9640	II
Opium Poppy/Poppy Straw.	9650	II
Noroxymorphone	9668	П
Poppy Straw Con- centrate.	9670	II
Tapentadol	9780	П

The company plans to import Phenylacetone (8501), and Poppy Straw Concentrate (9670) to bulk manufacture other controlled substances for distribution to its customers. The company plans to import an intermediate form of Tapentadol (9780) to bulk manufacture Tapentadol for distribution to its customers. In reference to drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), the company plans to import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

#### Claude Redd,

Acting Deputy Assistant Administrator. [FR Doc. 2023–24614 Filed 11–7–23; 8:45 am] BILLING CODE P

#### **DEPARTMENT OF JUSTICE**

# Drug Enforcement Administration [Docket No. DEA-1286]

## **Bulk Manufacturer of Controlled Substances Application: Noramco**

**AGENCY:** Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

**SUMMARY:** Noramco has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before January 8, 2024. Such persons may also file a written request for a hearing on the application on or before January 8, 2024.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on October 04, 2023, Noramco, 500 Swedes Landing Road, Wilmington, Delaware 19801–4417, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	1
Marihuana	7360	1
Tetrahydrocannabinols	7370	1
Codeine-N-oxide	9053	1
Dihydromorphine	9145	1
Hydromorphinol	9301	1
Morphine-N-oxide	9307	1
Amphetamine	1100	II
Lisdexamfetamine	1205	II
Methylphenidate	1724	II